【レポートの概要（一部）】
1. Executive Summary
1.1 Next-Generation Biologics: World Market Review 2014
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Research and Analysis Methods
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.4 An Introduction to Next-Generation Biologics
1.4.1 A Brief History of Biological Drug Development
1.4.2 Limitations to Current Generation Biologics
1.4.3 The Promise of Next-Generation Biologics
1.4.3.1 Defining Next-Generation Biologics
1.4.3.2 A Definition of Regenerative Medicine
1.4.3.3 Extending Half-Life: Pegylation and Other Novel Strategies
2. The World Next-Generation Biologics Market: Outlook and Forecast 2014-2024
2.1 The Next-Generation Biologics Market 2013
2.1.1 Development of the Next-Generation Biologics Market 2008-2013
2.1.2 Rising Demand for Biological Therapies
2.1.3 Next-Generation Drugs as a Share of the Biologics Market 2013
2.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
2.1.5 Leading Companies in the Next-Generation Biologics Market 2013
2.2 The Next-Generation Biologics Market 2014-2024
2.2.1 The Biologics Market Forecast 2014-2024
2.2.1.1 Growth Drivers for Biological Drug Revenues 2014-2024
2.2.2 The Next-Generation Biologics Market Forecast 2014-2024
2.2.3 Product Launches in All Sectors to Drive Market Growth 2014-2024
2.2.4 Next-Generation Biologics: Market Restraints 2014-2024
2.2.5 Rising Market Shares for Next-Generation Insulins 2014-2024
3. Leading National Submarkets for Next-Generation Biologics 2014-2024
3.1 Leading National Submarkets for Next-Generation Biologics 2013
3.1.1 National Submarket Forecasts 2014-2024
3.1.2 How Will National Submarket Shares Change to 2024?
3.2 Rising Disease Incidence in Major Markets 2014-2024
3.3 Approval of Next-Generation Biologics in Major National Submarkets
3.4 The US Will be the Largest Submarket for Next-Generation Biologics 2014-2024
3.4.1 US Submarket Forecast 2014-2024
3.5 Next-Generation Biologics in Japan 2014-2024
3.5.1. National Expertise in Stem Cell Research
3.5.2 Japanese Submarket Forecast 2014-2024
3.6 Next-Generation Biologics in Leading EU Nations 2014-2024
3.6.1 Regenerative Medicine Development in the EU
3.6.2 Market Access for Next-Generation Biologics in the EU
3.6.3 Germany: Submarket Forecast 2014-2024
3.6.4 France: Submarket Forecast 2014-2024
3.6.5 UK: Submarket Forecast 2014-2024
3.6.6 Italy and Spain: Submarket Forecasts 2014-2024
3.7 Next-Generation Biologics in Emerging Markets 2014-2024
3.7.1 Next-Generation Biologics Development in Emerging Markets
3.7.2 Chinese Submarket Forecast 2014-2024
3.7.3 Indian Submarket Forecast 2014-2024
4. Next-Generation Antibodies Submarket Outlook 2014-2024
4.1 Strategies for Improving Antibody Therapies
4.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
4.1.2 Engineering Antibodies for Improved Potency
4.1.3 Bispecific Antibodies
4.2 Next-Generation Antibody Therapy Submarket 2012-2013
4.3 Next-Generation Antibody Therapy Submarket 2014-2024
4.3.1 Strong Revenue Growth for Next-Generation Antibodies 2014-2024
4.3.2 Blockbuster Potential Will Drive Growth to 2024
4.3.3 Next-Generation Antibodies: Submarket Restraints 2014-2024
4.4 Antibody-Drug Conjugates Submarket 2014-2024
4.4.1 Antibody-Drug Conjugates Submarket Forecast 2014-2024
4.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2014-2024
4.4.2 What Will Drive Growth for ADCs to 2024?
4.4.3 A Long Pipeline of ADCs in Clinical Development
4.4.3.1 CMC544: NHL Development Halted but Trials in ALL Continue
4.4.3.2 CDX-011: Potential for Accelerated Approval in Breast Cancer
4.5 Engineered Antibodies Submarket 2014-2024
4.5.1 Engineered Antibodies Submarket Forecast 2014-2024
4.5.1.1 Gazyva Will Lead the Submarket in 2024
4.5.2 Portfolio Management to Drive Growth 2014-2024
4.5.3 Engineered Antibodies Pipeline 2014
4.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
4.6 Bispecific Antibodies Submarket 2014-2024
4.6.1 Bispecific Antibodies Submarket Forecast 2014-2024
4.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2014-2024
4.6.3 One Phase III and Two Phase II Bispecific Antibodies in 2014
4.6.3.1 Blinatumomab (Amgen): The Only Phase III Bispecific Antibody
5. Antibody Fragments and Novel Antibody-Like Drugs: Commercial Potential 2014-2024
5.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
5.1.1 Antibody-Like Proteins Mimic Antibody Therapies
5.1.2 There Are Advantages to Using Fragments and Novel Scaffolds
5.2 Antibody Fragment and ALP Submarket 2014-2024
5.2.1 Antibody Fragment and ALP Submarket Forecast 2014-2024
5.2.2 Pharma Is Investing Strongly in Antibody Fragments and ALPs
5.2.3 Limited Late-Stage Pipeline to Restrain Growth to 2024
5.3 Outlook for Next-Generation Antibody Fragments 2014-2024
5.3.1 Next-Generation Antibody Fragment Submarket Forecast 2014-2024
5.3.2 One Platform Leads the Pipeline in 2014
5.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
5.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
5.4 The Antibody-Like Protein Submarket 2014-2024
5.4.1 Antibody-Like Protein Submarket Forecast 2014-2024
5.4.2 Four ALPs in Clinical Development in 2014
5.4.2.1 AGN-150998: Development of the Lead Clinical ALP Delayed
5.5 Will Next-Generation Immunotoxins Impact the Market to 2024?
5.5.1 Challenges with First Generation Immunotoxins
5.5.2 Fusion Protein Conjugates: Pipeline 2014
5.5.2.1 Moxetumomab Pasudotox
5.5.3 Humanised Immunotoxins
5.5.3.1 Using Granzyme B in Immunotoxins
5.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
6. Next-Generation Insulin Submarket: Outlook 2014-2024
6.1 Strategies for Next-Generation Insulin Development
6.1.1 Reformulating Insulin for Convenient Administration
6.1.1.1 Oral Insulin
6.1.1.2 Inhaled Insulin
6.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
6.2 Next-Generation Insulin Submarket 2012-2013
6.2.1 Tresiba: Approved in the EU and Japan
6.2.1.1 Tresiba: Revenue Forecast 2014-2024
6.3 Next-Generation Insulin Submarket 2014-2024
6.3.1 Next-Generation Insulin Submarket Forecast 2014-2024
6.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2014-2024
6.3.3 Next-Generation Insulin Submarket Restraints 2014-2024
6.3.3.1 Biosimilar Insulins Will be Available from 2015
6.4 Oral Insulin Submarket 2014-2024
6.4.1 Oral Insulin Submarket Forecast 2014-2024
6.4.2 Oral Insulin: Submarket Drivers and Restraints 2014-2024
6.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2014
6.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
6.4.3.2 Novo Nordisk
6.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
6.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
6.5 Ultra-Rapid Acting Insulin Submarket 2014-2024
6.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2014-2024
6.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2024?
6.5.2 Other Submarket Drivers and Restraints 2014-2024
6.5.3 Ultra-Rapid Acting Insulin Pipeline 2014
6.5.3.1 FIAsp (Novo Nordisk)
6.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
6.5.3.3 Halozyme Therapeutics
6.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
6.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
6.5.3.6 Adagio: A Second-Generation Inhaled Insulin
6.6 Ultra-Long Acting Insulin Submarket 2014-2024
6.6.1 Ultra-Long Acting Insulin Submarket Forecast 2014-2024
6.6.2 Revenue Growth Driven by Uptake of Tresiba
6.6.3 Ultra-Long Acting Insulin Pipeline 2014
6.6.3.1 U300: Sanofi’s Next-Generation Insulin Analogue
6.6.3.2 LY2605541 (Eli Lilly)
6.6.3.3 FT-105 (Flamel Technologies)
6.6.3.4 LAPS-Insulin
7. Next-Generation Developments for Other Recombinant Proteins 2014-2024
7.1 Defining Next-Generation for Other Recombinant Protein Sectors
7.1.1 Next-Generation Interferon Beta: Plegridy Set for Approval in 2014
7.1.1.1 Plegridy: Revenue Forecast 2014-2024
7.1.1.2 Plegridy May Compete with Other Long-Acting Interferon Beta Therapies 2014-2024
7.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
7.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2014
7.2 Next-Generation Recombinant Coagulation Factors 2014-2024
7.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2014-2024
7.2.2 Submarket Drivers and Restraints 2014-2024
7.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2014-2024
7.2.3.1 BAX 855 (Baxter)
7.2.3.2 BAY94-9027 (Bayer)
7.2.3.3 N8-GP for Haemophilia A
7.2.3.4 N9-GP for Haemophilia B
7.2.3.5 Fused Factors: Biogen Idec’s Eloctate and Alprolix
7.2.3.6 rIX-FP (CSL Behring): Albumin-Bound Coagulation Factors
7.2.4 Gene Therapy as a New Treatment Option for Haemophilia
7.3 Next-Generation Growth Hormones 2014-2024
7.3.1 Next-Generation Growth Hormone Submarket Forecast 2014-2024
7.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormones 2014-2024
7.3.3 Long-Acting Growth Hormones
7.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
7.3.3.2 Prolor Biotech/OPKO Health
7.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
7.3.3.4 Versartis: XTEN Technology for Half-Life Extension
7.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
7.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
8. Regenerative Medicine: Commercial Outlook 2014-2024
8.1 The Regenerative Medicine Submarket 2012-2013
8.1.1 Defining Regenerative Medicine
8.2 The Regenerative Medicine Submarket: Revenue Projections 2014-2024
8.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2014-2024
8.3 The Stem Cell Therapies Submarket 2014-2024
8.3.1 Prochymal (Mesoblast) for GvHD
8.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
8.3.2 A Note on Stem Cell Transplants
8.3.3 Stem Cell Therapies Submarket Forecast 2014-2024
8.3.4 Stem Cell Therapies: Submarket Drivers and Restraints 2014-2024
8.3.4.1 Will iPSCs Prove Effective for Stem Cell Therapy?
8.3.5 Stem Cell Therapies Late-Stage Pipeline 2014
8.3.5.1 Cx601 (TiGenix)
8.3.5.2 Mesoblast: Mesenchymal Stem Cell Therapies
8.3.5.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
8.3.5.4 StemEx (Gamida Cell)
8.4 The Gene Therapies Submarket 2014-2024
8.4.1 Glybera Approved and Set for Launch in the EU
8.4.2 Gene Therapies Submarket: Revenue Projections 2014-2024
8.4.3 Glybera’s Approval to Drive Submarket Growth from 2014
8.4.4 There Are More Than Five Gene Therapies in Late-Stage Development
8.4.4.1 ProstAtak: Gene Therapy for Prostate Cancer
8.4.4.2 TVEC (Amgen)
8.4.4.3 Generx (Cardium Therapeutics)
8.4.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
8.5 Outlook for Tissue Engineering 2014-2024
8.5.1 Two Sectors Lead the Market: Wound and Cartilage Repair
8.5.1.1 Apligraf Leads the Wound Repair Submarket
8.5.1.2 Organogenesis Will Market Apligraf and Dermagraft from 2014
8.5.2 Tissue Engineering Submarket Forecast 2014-2024
8.5.3 Tissue Engineering: Submarket Drivers and Restraints 2014-2024
8.5.4 Future Developments in Cartilage Repair: Pipeline 2014
8.5.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
8.5.5.1 Engineered Skin
8.5.5.2 Engineered Veins
8.5.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9. Next-Generation Biologics: Industry Trends 2014-2024
9.1 Next-Generation Biologics: Market Strengths 2014
9.2 Next-Generation Biologics: Market Weaknesses 2014
9.3 The Next-Generation Biologics Market: STEP Analysis 2014-2024
9.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
9.3.1.1 Rising Incidence in Cancer, Diabetes and Cardiovascular Disease
9.3.1.2 Next-Generation Biologic Development in Emerging Markets
9.3.2 Technological Developments 2014-2024
9.3.3 Economic Pressures 2014-2024
9.3.3.1 High Drug Costs and Healthcare Spending
9.3.3.2 Limited Commercial Potential in Emerging Markets?
9.3.4 Political Issues: Regulatory Developments 2014-2024
9.4 Next-Generation Biologics: Development Trends 2014-2024
9.4.1 Improving Patient Convenience
9.4.2 Sustained Release Biologics: Pegylation and Beyond
9.4.3 Therapeutic Focus for Next-Generation Biologics
9.4.4 Next-Generation Biologics as Personalised Medicine
9.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
9.5.1 Contract Manufacturers Invest to Follow Development Trends
9.6 Commercialising Next-Generation Biologics
9.6.1 Product Lifecycle Management for First Generation Biologics
9.6.2 Proving Benefit in Next-Generation Products
9.6.3 Biosimilars as a Challenger 2014-2024
9.7 Partnering for Next-Generation Biologic Development
9.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
9.7.2 Most Development Platforms Stem from Small Biotechs
10. Research Interviews from Our Survey
10.1 Dr Fredrik Frejd, CSO, Affibody
10.1.1 Affibody
10.1.2 Challenges with Current Biological Therapies
10.1.2.1 Current Half-Life Extension Technologies
10.1.3 The Benefits of Affibodies Over Current Antibody Therapies
10.1.4 Focus on Inflammation and Autoimmune Diseases
10.1.5 Development of SOBI002
10.1.6 Regulatory Challenges for Novel Biologics
10.2 Dr Mike Romanos, CEO, Crescendo Biologics
10.2.1 Crescendo Biologics
10.2.2 The Benefits in Antibody Fragment Therapies
10.2.3 Treatment of Inflammation Indications with Antibody Fragments
10.2.4 Crescendo’s Fragment Pipeline
10.2.5 Development and Production Platforms for Antibody Therapies
11. Conclusions to Our Study
11.1 The Next-Generation Biologics Market Will Grow Strongly to 2024
11.2 Next-Generation Antibody Development Will Lead the Market
11.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
11.4 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル：次世代バイオロジックス（生物製剤）市場：技術、産業、市場（2014-2024）■ 英文：Next-Generation Biologics: R&D, Industry and Market 2014-2024
■ 発行日：2014年4月
■ 調査会社：visiongain
■ 商品コード：Visiongain-405311
■ 調査対象地域：グローバル
- エピウエハーの世界市場2017-2021ABSTRACTAbout Epi Wafer Epitaxy is the process of depositing a crystalline layer over a crystalline-based semiconductor substrate or surface. Epitaxial devices comprise nanolayers of semiconductor crystals that are uniformly deposited on deposition tools to form an epi-wafer. Combining different semiconductor materials and dopants in an epi wafer helps determine the performance capabilities of pho …
- 世界の自動車用接着剤市場2015The Global Automotive Adhesives Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Automotive Adhesives industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Automotive Adhesives market analysis is provided for the international markets including develop …
- 世界における小型自動車用ルーフシステム市場動向と予測（～2029）This latest just-auto report edition offers a global review of the OE roof systems sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE roof systems market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prosp …
- 舗装機械・コンクリート装置の世界市場2017-2021About Paving and Concreting Equipment Paving and concreting equipment are used to perform tasks such as paving, grading, compacting, concreting, and supply and mixing of concrete on the construction site. Paving and concreting equipment find applications in the infrastructure, building, and realty sector. The equipment include compactors, pavers, and concreting systems and pumps. Technavio’s analy …
- 世界のM2M通信市場（2014-2019）The array of connected devices is ever-broadening. Wireless communications are rapidly engulfing the automotive, healthcare, energy, and retail industries, as wirelessly connected endpoints appear on track to outnumber people. M2M encompasses a number of different markets and technologies, totalling $41.6 billion in revenue for 2014. The market includes 257.8 connected devices from a wide variety …
- 非スコッチウイスキーのグローバル市場動向と予測（～2018）Non-Scotch whiskies in aggregate represent an enormous and growing category, with Irish whiskey in particular showing real momentum. This new joint IWSR/just-drinks report provides the latest insight into one of the most dynamic of categories. Yet despite the positive outlook for the whisk(e)y industry, there are challenges and potential challenges ahead. The report looks at the most importan …
- IDaaS（サービスとしてのアイデンティティ）の世界市場予測（～2024年）Growing demand for cloud-based security solutions and services to drive the adoption of Identity as a Service (IDaaS) marketThe IDaaS market is projected to grow from USD 2.5 billion in 2019 to USD 6.5 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 21.1% during the forecast period. The fast growth in IT infrastructure has given rise to new vulnerabilities and threats. The cloud-based …
- 熱処理空気ろ過の世界市場2017-2021About Thermal Treatment Air FiltrationThermal treatment air filtration is a method wherein heat is used to filter industrial air streams to prevent hazardous pollutants from being emitted into the atmosphere. In this technique, exhaust air is thermally heated to very high temperatures in an oxidizer chamber, which breaks down the chemical bonds of the pollutant compounds. The compounds then combin …
- OSDF用高分子系溶解性向上賦形剤の世界市場2017-2021About Polymer Based Solubility Enhancement Excipients for OSDF The behavior of drugs with regard to solubility has been one of the most crucial aspects of developing a formulation. Drug formulations are adversely affected by poor solubility and low permeability. Approximately 40% of the modern drugs that are marketed is classified by the Biopharmaceutical Classification System (BCS) into two subca …
- 建設用シーラント剤の世界市場2017-2021About Construction Sealants Sealants, also known as caulking agents, are used to fill vacant spaces in mechanical joints to prevent the passage of liquid and gas. They are widely used in the building and construction industry for waterproofing, window and door sealing, bathroom sealing, roof sealing, and fireproofing. The global construction sealants market is segregated based on the type of resin …
- 軍事リースの世界市場2016-2026Now: Why is the Military Leasing important right now? As part of the broader Military Leasing market space, there are massive revenue streams within the unmanned systems submarket to tap into. This report shows you where these business opportunities are. Due to a myriad of real and perceived threats, never before have government and private enterprise been so concerned with protecting their busine …
- 鞭虫症(Trichuriasis)：世界の治験レビュー2014年下半期版Trichuriasis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Trichuriasis Global Clinical Trials Review, H2, 2014" provides data on the Trichuriasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trichuriasis. It includes an overview of the trial numbers and their recruitment status as per the sit …
- フレキシブル紙パッケージングの世界市場2015-2019About flexible paper packaging Flexible paper packaging is environmental-friendly and cost-effective. The different types of paper used for packaging are uncoated kraft paper, coated kraft paper, sack kraft paper, and gift wraps. These paper packaging products are used in different applications such as paper bags, multiwall sacks, containerboard, and boxboard. Vendors in the global flexible paper …
- 病院用物流ロボットの世界市場2018-2022About Hospital Logistics Robots Hospital logistics robots comprise autonomous guided vehicles (AGVs) and mobile robot platforms. These are used for managing the flow of goods such as laboratory samples, food, pharmaceuticals, environmental waste, and laundry inside hospital premises. Technavio’s analysts forecast the global hospital logistics robots market to grow at a CAGR of 15.48% during the pe …
- 心調律管理（CRM）医療装置のグローバル市場（2012-2018）The Cardiac Rhythm Management Devices market value is expected to reach US$20.9 billion by 2017, primarily supported by the product types - Cardiac Defibrillators, Cardiac Pacemakers Devices and Cardiac Resynchronization Therapy. Globally, Cardiac Defibrillators and Pacemakers Devices together account for approximately 80% of the market share to support the Cardiac Rhythm Management Devices Indust …
